Drug Type Monoclonal antibody |
Synonyms RG 6440, RG-6440, RG6440 + [5] |
Target |
Action inhibitors |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Solid Tumor | Phase 1 | United States | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | United States | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Japan | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Japan | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Australia | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Australia | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Brazil | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Brazil | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Italy | 02 Oct 2023 | |
Metastatic Solid Tumor | Phase 1 | Italy | 02 Oct 2023 |
Phase 1 | - | sgrqbmzxdx(uxjlyoffey) = One dose-limiting toxicity (liver disorder) was seen with SOF10 (600 mg) + atezolizumab xdrepvwffy (jyuvmxpske ) View more | - | 14 Sep 2024 |